Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neil Shah

Hospitalist Tuscaloosa, AL Medical Doctor

NPI 1013235100 CMS profile 1296061

100 Rice Mine Rd N Ste 100, Tuscaloosa, AL 35406

Open in the dashboard

General payments

$4,189

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Neil Shah of Tuscaloosa, AL is reported in the CMS Open Payments database as having received $4,189 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $616 29
2024 General $633 39
2023 General $717 39
2022 General $964 54
2021 General $702 35
2020 General $277 11
2019 General $281 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neil Shah
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Neil Shah were reported at $616. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Neil Shah Hospitalist median Middle half National median
2019 $281 $96 $28–$201 $163
2020 $277 $48 $19–$125 $114
2021 $702 $70 $23–$167 $132
2022 $964 $85 $27–$174 $149
2023 $717 $89 $30–$191 $160
2024 $633 $95 $29–$204 $164
2025 $616 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $983 47 payments
  2. Pfizer Inc. $436 27 payments
  3. Novo Nordisk Inc $297 17 payments
  4. AbbVie, Inc. $252 12 payments
  5. Dexcom, Inc. $252 13 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $235 13 payments
  7. Lilly USA, LLC $228 14 payments
  8. Otsuka America Pharmaceutical, Inc. $190 9 payments
  9. Novartis Pharmaceuticals Corporation $171 11 payments
  10. AstraZeneca Pharmaceuticals LP $115 8 payments
  11. Other $1,031 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,189 225 payments
Products named General payments · program years 2019–2025
  1. XARELTO $983 47 payments
  2. ELIQUIS $368 21 payments
  3. Dexcom G6 Transmitter $235 12 payments
  4. Kerendia $235 13 payments
  5. NURTEC ODT $178 12 payments
  6. MOUNJARO $168 10 payments
  7. PAXLOVID $153 8 payments
  8. RYBELSUS $141 9 payments
  9. VRAYLAR $137 7 payments
  10. REXULTI $127 6 payments
  11. Other $2,062 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 181 drugs

Part D claims

10,779

Median for Internal Medicine: 777

Drug cost

$876,795

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 206 $109,467
Ozempic Semaglutide Brand 67 $87,700
Mounjaro Tirzepatide Brand 48 $52,962
Trulicity Dulaglutide Brand 36 $49,679
Jardiance Empagliflozin Brand 61 $45,570
Xarelto Rivaroxaban Brand 46 $37,272
Nuedexta Dextromethorphan Hbr/Quinidine Brand 56 $35,791
Januvia Sitagliptin Phosphate Brand 61 $34,250
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 47 $32,090
Xifaxan Rifaximin Brand 18 $28,602

The 10 drugs with the highest cost, of 181 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$108,162

Of which drugs: $2,805

Medicare patients

427

Average age 75

Services billed

1,753

221 women, 206 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 45%
Chronic kidney disease 41%
Depression 39%
Ischemic heart disease 38%
Heart failure 33%
COPD 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 19 19 $686
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 11 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $71
$71 206 —
NURTEC ODT
  • PFIZER INC. $59
$59 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $57
$57 46 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $56
$56 44 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospitalist in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record